bf/NASDAQ:ELVN_icon.jpeg

COM:ENLIVENTHERAPEUTICS

Enlivex Therapeutics Ltd.

  • Stock

Last Close

27.65

05/11 21:00

Market Cap

1.08B

Beta: -

Volume Today

222.33K

Avg: -

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been...Show More

investor of